[Antisense oligonucleotide against survivin induces apoptosis and enhances adriamycin sensitivity of SMMC-7721/ADM cells].
OBJECTIVE
To explore the effects of survivin-specific antisense oligonucleotide (ASODN) delivered via liposome on the growth and apoptosis of drug-resistant human hepatic cancer cell line SMMC-7721/ADM and the sensitivity of the cells to adriamycin (ADM).


METHODS
SMMC-7721/ADM cells were divided into 6 groups and treated with liposome, ADM, sense oligonucleotide (SODN), SODN+ADM, 400 ng/ml ASODN, and 400 ng/ml ASODN+ADM group, respectively. MTT assay was used to calculate the relative survival rates of the cells, and the changes in cell apoptosis and cycle were detected with flow cytometry. RT-PCR and Western blotting were performed to detect the expressions of survivin mRNA and protein, respectively.


RESULTS
The apoptotic rate of ASODN-treated cells was much higher than that of the control cells. survivin protein expression showed no significant variation between cells treated with liposome, ADM, SODN, and SODN+ADM (P>0.05), whereas compared with these 4 groups, cells treated with 400 ng/ml ASODN and 400 ng/ml ASODN+ADM had significantly lowered survivin mRNA expression (P<0.05), without significant differences between the latter two groups (P>0.05). SMMC-7721/ADM cells cultured in the presence of ASODN and adriamycin showed significant growth inhibition in comparison with ASODN group and ADM group.


CONCLUSIONS
survivin-specific ASODN can enhance the sensitivity of SMMC-7721/ADM cells to ADM by depressing survivin expression in the cells, thus improves the effect of ADM chemotherapy for liver cancer.
Gao
Peng
P
Department of Hepatobiliary Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China.
Fang
Chi-hua
CH
Zhang
Gang-qing
GQ
Yan
Zheng
Z
D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects* / Q000235:genetics / Q000502:physiology; D015153:Blotting, Western; D006528:Carcinoma, Hepatocellular / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004317:Doxorubicin / Q000494:pharmacology*; D019008:Drug Resistance, Neoplasm; D005434:Flow Cytometry; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins; D008081:Liposomes / Q000737:chemistry; D008113:Liver Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D008869:Microtubule-Associated Proteins / Q000235:genetics* / Q000378:metabolism; D009363:Neoplasm Proteins / Q000235:genetics* / Q000378:metabolism; D016376:Oligonucleotides, Antisense / Q000737:chemistry / Q000235:genetics*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D000077022:Survivin; D014162:Transfection / Q000379:methods
D000903:Antibiotics, Antineoplastic; C107489:BIRC5 protein, human; D051034:Inhibitor of Apoptosis Proteins; D008081:Liposomes; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D016376:Oligonucleotides, Antisense; D012333:RNA, Messenger; D000077022:Survivin; D004317:Doxorubicin